Compare The Coca-Cola Co K (KO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs State Street SPDR S&P Biotech ETF — how do they compare? The Coca-Cola Co K trades at $81.92 (market cap $353.32B), while State Street SPDR S&P Biotech ETF trades at $153.4. The key difference: The Coca-Cola Co K pays a 2.58% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| KO | XBI | |
|---|---|---|
Market Cap | $353.32B | — |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $84.92 | $164.28 |
52-Week Low | $65.67 | $85.16 |
Enterprise Value | $383.39B | — |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.87, up 0.38% today, with a neutral technical signal and strong fundamentals including a 27.8% net income margin and consistent earnings beats. The stock shows robust profitability with ROE at 45.8% and a dividend yield supported by 64 consecutive years of increases. Recent news highlights institutional buying and stable demand trends ahead of Q2 2026 earnings.
Outlook remains positive with a consensus price target of $90.67, implying ~11% upside. Risks include regional demand divergence and high debt levels. Analyst sentiment is bullish (60% Buy ratings), but investors should monitor execution against earnings expectations and macroeconomic pressures on consumer spending.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
